Press Release

15 Articles found

News Press Releases Locus Insights

August 12, 2024

Locus Biosciences Announces Positive Results from Part 1 of ELIMINATE Phase 2 Trial of the Engineered Bacteriophage Therapy LBP-EC01 Published in The Lancet Infectious Diseases

Learn More
January 23, 2024

Locus Biosciences Announces $23.9 Million in Funding from BARDA to Support First Phase 2 Trial of CRISPR-engineered Bacteriophage Therapy

Learn More
September 13, 2022

Locus Biosciences Announces First Patient Treated in the ELIMINATE Registrational Phase 2/3 Trial of LBP-EC01 for Urinary Tract Infections

Learn More
May 18, 2022

Locus Biosciences Announces $35 Million Financing

Learn More
October 19, 2021

Locus Biosciences Secures Financing of up to $25 Million from Hercules Capital. Proceeds to be used to advance development of synthetic biology engine and manufacturing capabilities

Learn More
February 24, 2021

Locus Biosciences completes first-of-its-kind controlled clinical trial for CRISPR-enhanced bacteriophage therapy

Learn More
November 10, 2020

Locus Biosciences signs contract with CARB-X to advance $14 million precision medicine program to develop crPhage™ product targeting Klebsiella pneumoniae infections

Learn More
September 30, 2020

Locus Biosciences signs contract with BARDA to advance $144 million precision medicine program to develop LBP-EC01, a crPhage™ product

Learn More
January 8, 2020

Locus Biosciences initiates world’s first controlled clinical trial for a CRISPR enhanced bacteriophage therapy

Learn More
January 3, 2019

Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics

Learn More